Case Study: Achieving Accelerated Approval for a Novel Oncology Agent

In 2024, Mevoq partnered with a client developing a novel targeted therapy for metastatic non-small cell lung cancer (NSCLC). The standard approval pathway would have required overall survival (OS) data, necessitating a trial duration of 5+ years. Our strategy focused on validating Objective Response Rate (ORR) as a surrogate endpoint reasonably likely to predict clinical benefit.

We facilitated three Critical Path Innovation Meetings (CPIM) with the FDA to align on the statistical analysis plan for the single-arm Phase 2 trial. By demonstrating the high correlation between ORR and OS in historical control data, we secured the agency’s agreement to accept the surrogate endpoint.

The result was an NDA submission 36 months earlier than originally projected. The drug received Accelerated Approval, allowing the client to generate revenue while confirming clinical benefit in a post-marketing confirmatory trial. This case highlights the value of aggressive, scientifically-backed regulatory negotiation.